Organic Chemistry Methods TRIZ Cases

A 2-substituted triphenylene core minimizes molecular deformation during hole transfer, lowering OLED driving voltage and extending service life.

Conventional organic electroluminescent elements trade off efficiency and service life; fused polycyclic compounds address both in functional layers.

Combining Gabapentin and Ketoprofen with Lysine in a 1:1:2 co-crystal targets neuropathic and inflammatory pain while improving solubility and bioavailability.

KIF18A-targeting amide or urea compounds address CIN-driven mitotic errors by inducing tumor-cell arrest and apoptosis while sparing normal proliferation.

Amorphous fumarate forms create stability and formulation hurdles; crystalline polymorphs improve thermal stability, flowability, and solubility.

Amorphous or oily starting material can introduce impurities; a non-solvate free base crystal enables cleaner monophosphate salt preparation.

A novel organic compound balances hole transport and exciton confinement to support low voltage, color purity, and longer element life.

Controlled crystallization creates stable VCP/p97 inhibitor forms, with XRPD, TGA, and DSC verifying polymorphs and thermal behavior.

Triplet-triplet annihilation converts wasted triplet excitons into delayed fluorescence, improving emission efficiency in organic light-emitting layers.

Traditional beta-caryophyllene oxidation can be slow and reagent-heavy; atmospheric oxygen and controlled heating produce caryophyllene oxides without catalysts or solvents.

α-Helix-mimicking peptidomimetics induce ER stress and shut down de novo protein synthesis to inhibit therapy-resistant cancer cells.

Selective deuterium substitution and a dual-host light-emitting layer address OLED efficiency, driving-voltage, and lifetime trade-offs.

Deuterium-substituted amine compounds in the hole transport region improve luminous efficiency and extend light-emitting element lifespan.

Deuterium-substituted amine compounds in the hole transport region improve charge transportability, luminous efficiency, and element lifespan.

KRED enzymes replace costly conventional synthesis to improve yield and selectivity when preparing beta-3 agonists and intermediates.

A composite emitting layer combines Formula 1 with Formula 2 or 3 compounds to improve efficiency and stability while lowering driving voltage and extending service life.

Specific metal-complex and companion compounds in the OLED organic layer target short lifetime, color saturation, and efficiency roll-off.

Heating oxidizes the palladium compound before dissolution and carrier contact, improving support stability and catalyst reproducibility across carriers.

Low-yield olefin carbonylation is addressed with a supported palladium catalyst and ammonium chloride to limit metal precipitates.

Deuterium substitution changes dopant behavior to narrow organic EL emission while supporting higher EQE and longer device lifetime.

ZADN and ETM-07 in the cathode-side blue stack improve electron transport while addressing efficiency, voltage, and stability trade-offs.

Trans-1,4-cyclohexane structures address limited carrier mobility and heat stability while supporting flexible, cost-effective organic transistor production.

Deuterium-containing compounds alter OLED material composition to extend device lifetime while preserving electroluminescent operation.

Triplet-emission OLEDs use aromatic lactam matrix compounds with tuned energy levels to improve efficiency, reduce operating voltage, and extend lifetime.

An organometallic compound in the OLED interlayer improves carrier recombination to raise luminance and response speed.

Formula 1 polycyclic compounds in the organic layer address limited OLED lifespan while maintaining light-emission functionality.

Flow-synthesis catalysts can lack selectivity and stability; a tuned alumina–silica–magnesium oxide carrier supports palladium for ≥85% targeted reduction.

Rigid conjugated boron-nitrogen structures limit molecular vibration and rotation, enabling narrow OLED emission, high efficiency, and longer operational life.

Deuterium-substituted amine compounds improve hole transport and help extend service life in organic electroluminescent elements.

Crystalline polymorphs, salts, and co-crystals address Aprocitentan’s processing, stability, dissolution, and bioavailability needs.

Characterized amorphous and crystalline Compound 1 forms support stability, handling, and oral bioavailability while enabling controlled pharmaceutical manufacture.

Specific polyester and polyester carbonate units balance refractive index and b value while improving heat and moist-heat resistance in optical lenses.

Crystalline Mirdametinib complexes address stability and handling challenges through defined solid-state forms for pharmaceutical compositions.

Composite host materials combine distinct compounds to balance OLED luminous efficiency, driving voltage, and lifetime.

Novel EGFR compounds target del19/L858R T790M C797S variants with improved brain penetration and reduced wild-type EGFR activity.

Specific organometallic compounds in the OLED emission layer target high driving voltage and short lifespan while preserving efficiency.

Selective deuterium substitution in OLED emitting compounds improves luminous efficiency and lifetime while avoiding the cost of fully deuterated materials.

Conventional solvent-based routes can lower selectivity and yield; supported composite catalysis converts vicinal diols with hydrogen under solvent-free conditions.

Clopidogrel variability, resistance, and slow activation are addressed with modified compounds designed for consistent platelet aggregation inhibition.

An early chiral auxiliary, Wittig reaction, and Makosza cyclopropanation avoid chiral HPLC while supporting industrial synthesis without racemization.